Related Experiment Video
Updated: Jun 3, 2026
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Factor XIII and venous thromboembolism.
Zsuzsanna Bereczky1, László Muszbek
1Clinical Research Center and Thrombosis, Haemostasis and Vascular Biology Research Group, Hungarian Academy of Sciences, University of Debrecen, Medical and Health Science Center, Debrecen, Hungary.
Seminars in Thrombosis and Hemostasis
|April 2, 2011
Summary
Plasma factor XIII (FXIII) is crucial for hemostasis. This review explores FXIII
Area of Science:
- Biochemistry
- Hematology
- Molecular Biology
Background:
- Plasma factor XIII (FXIII) is a zymogen essential for hemostasis, playing roles in clot stabilization and fibrinolysis regulation.
- Severe FXIII deficiency leads to severe bleeding disorders, but its role in thrombotic diseases is less understood.
Purpose of the Study:
- To provide an overview of the relationship between factor XIII and venous thromboembolism (VTE).
- To review and analyze existing literature on FXIII and VTE risk.
- To examine the association between FXIII-A polymorphism and VTE risk.
Main Methods:
- Literature review and synthesis of publications on FXIII and VTE.
- Focus on studies investigating FXIII-A polymorphisms and their association with VTE.
Main Results:
- FXIII is vital for hemostasis, strengthening fibrin clots and regulating fibrinolysis.
- The association between FXIII and thrombotic diseases, particularly VTE, is an area of ongoing research.
- FXIII-A polymorphisms have garnered significant interest regarding their potential link to VTE risk.
Conclusions:
- Factor XIII plays a critical role in hemostasis and clot structure.
- Further research is needed to clarify the complex relationship between FXIII and venous thromboembolism.
- Investigating FXIII-A polymorphisms may offer insights into VTE risk stratification.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...